Genetic Testing for Eye Disease: When It Helps and How to Read Results
Genetic testing is most useful when it answers a specific clinical question: what is causing a suspected inherited eye disorder, what does it mean for relatives, or could a patient meet criteria for a targeted treatment? It is not a general screen that predicts every future eye disease or guarantees a personalized cure.
Start with the eye findings and family history
A specialist may recommend testing for suspected inherited retinal disease, certain early-onset disorders or a known familial variant. Retinitis pigmentosa and Leber congenital amaurosis each have many possible genetic causes. Some disorders also affect organs outside the eye. The examination and genetic report should be interpreted together.
A family history is useful even if the exact diagnosis is uncertain. Record which relatives had problems, approximate age at onset and whether they had night-vision difficulty, field loss, hearing problems or other relevant findings. Absence of an affected relative does not rule out an inherited disorder.
Which test might be offered?
- Targeted testing: checks a known familial variant or a specific suspected gene.
- A gene panel: assesses a defined group of genes associated with a clinical pattern.
- Exome or genome sequencing: may be considered when broader investigation is appropriate. Broader testing can also produce more uncertain or unexpected findings.
Blood, saliva or a cheek sample may be used, depending on the laboratory. Before collection, ask what the test includes, what it misses, and whether additional analysis might be needed. The largest panel is not automatically the most useful choice.
Three result categories that should not be confused
| Result | What to discuss |
|---|---|
| Pathogenic or likely pathogenic finding | Does the finding fit the symptoms and inheritance pattern? A result may support a diagnosis or carrier status, but does not precisely predict future severity. |
| Negative | No relevant cause was identified by this test. Some causes may lie outside its coverage or current knowledge; continued clinical care may still be necessary. |
| Variant of uncertain significance (VUS) | The evidence is insufficient to classify the change as disease-causing or benign. It is not a confirmed explanation and should not be treated as automatic eligibility for gene therapy. |
Ask whether family testing, further clinical assessment or later reinterpretation could clarify the result. Keep the full report, including the laboratory, test date and variant classification.
Why ordinary AMD or glaucoma risk is a different question
Common age-related macular degeneration and typical late-onset open-angle glaucoma involve multiple influences. A susceptibility variant is not the same as a single-gene diagnosis. AAO guidance discourages routine genetic testing for these complex conditions unless it has demonstrated benefit for surveillance or treatment. Some congenital or early-onset glaucoma cases have a different rationale for testing.
Similarly, a list of reported keratoconus-associated genes is not a validated diagnostic test for everyone with astigmatism. Corneal assessment remains necessary. See astigmatism and the role of an eye examination.
Counseling before and after the test
Discuss possible results, emotional impact, implications for relatives, unexpected findings, privacy and consent. Ask who can access or retain the data and what protections apply where you live. Testing an unaffected child requires particular consideration of whether the information benefits the child now. A direct-to-consumer report needs clinical interpretation before it influences eye care.
A consultation checklist
- What decision could this test change?
- Who will explain a positive, negative or uncertain result?
- Could it identify a condition that needs non-eye assessment?
- What are the out-of-pocket costs and follow-up arrangements?
- Who should receive a copy, and how will reclassification be communicated?
Does a genetic diagnosis mean a treatment is available?
No. It may clarify a diagnosis or trial eligibility even when a targeted treatment is unavailable. For example, the US-approved RPE65 therapy has specific genetic and retinal eligibility requirements. See gene therapy: approved treatment versus research. Continue monitoring and visual support based on clinical needs rather than waiting for a test to provide every answer.
Sources and review
Reviewed October 28, 2026. General education; surgical eligibility and treatment require assessment by an ophthalmologist.